Previous 10 | Next 10 |
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-...
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia PR Newswire C linical trial assessing allogeneic, HLA-matched, donor-derived all...
Citi has initiated Gracell Biotechnologies ( NASDAQ: GRCL ) with a buy rating highlighting the speed of the company's autologous CAR-T platform manufacturing compared to competitors. The firm has a $12 price target (~422% upside based on Wednesday's close). Analyst Yig...
Gracell Biotechnologies Inc. (GRCL) Q2 2022 Earnings Conference Call August 15, 2022, 08:00 AM ET Company Participants Dr. Kevin Xie - CFO Dr. William Cao - Founder and CEO Dr. Wendy Li - Chief Medical Officer Conference Call Participants Joe Catanzar...
Gracell Biotechnologies press release ( NASDAQ: GRCL ): Q2 GAAP EPS of -$0.06 beats by $0.02 . As of June 30, 2022, the Company had RMB1,707.3 million (US$254.9 million) in cash and cash equivalents and short-term investments. In addition, For further details see...
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which underscored the deep response with a 100% MRD negativity rate Presented first-in-...
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022 PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a gl...
Gracell Biotechnologies ( NASDAQ: GRCL ) announced Monday the appointment of Wendy Li as its new chief medical officer. Li brings in over 20 years of experience in pharmaceutical industry across the US and China markets with expertise in leading early- and late-stage ...
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer PR Newswire Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, Chi...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...